What happened
Eli Lilly and Company (NYSE: LLY) found more weight loss by combining eloralintide with tirzepatide. It also found a bigger tolerability problem.
In a 48-week Phase 2b study of 367 adults with obesity or overweight and type 2 diabetes, the highest-dose EloraTZP regimen produced 23.3% average weight loss. Tirzepatide 15 mg alone produced 14.8%.
Read more: Eli Lilly and (LLY) stock analysis and investment case
Why it matters
EloraTZP combines eloralintide, a selective amylin receptor agonist, with tirzepatide's GIP and GLP-1 activity. The result supports Eli Lilly and Company (NYSE: LLY)'s effort to extend its obesity franchise beyond today's products.
The data do not settle the commercial case. The 23.3% figure comes from an efficacy analysis estimating results if assigned treatment continued for 48 weeks. The primary comparison was against placebo. Comparisons with tirzepatide were secondary.
Adverse-event discontinuations ranged from 10.8% to 27.0% across EloraTZP arms, versus 2.9% with tirzepatide. The release did not pair each dropout rate with each dose, so investors cannot assign the 27.0% rate to the top-dose efficacy result.
That distinction matters. Better average weight loss strengthens the pipeline case only if a practical dosing schedule keeps patients on treatment.
The countercase is that Phase 2 dose escalation was designed to test the medicine, not finalize commercial dosing. Eli Lilly and Company (NYSE: LLY) plans an optimized escalation schedule and a single-injection co-formulation in Phase 3. Those changes could improve tolerability, but that remains unproven.
Browse: stock research on every company OptimistFi covers
What's next
Watch Phase 3 for weight loss under the final schedule, adverse-event discontinuations by dose, and whether the efficacy holds in a larger population. Regulators will also need a full safety and efficacy package before approval.
EloraTZP strengthens evidence that Eli Lilly and Company (NYSE: LLY)'s pipeline can add efficacy beyond tirzepatide. It does not yet prove the combination can turn that efficacy into durable revenue or justify a premium valuation. This is source-backed research, not personalized investment advice.
More from OptimistFi
- LLY stock: the Eli Lilly and thesis, its status and the next test to watch
- Momentus Inc. (NASDAQ: MNTS) Completes NASA Satellite Test
- Tesla, Inc. (NASDAQ: TSLA) Q3 Consensus Splits Cars and Energy
- Dividendology Explains VICI Properties Inc. (NYSE: VICI)'s 8% Yield
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- Eli Lilly and Company (NYSE: LLY) EloraTZP Phase 2b results — Published September 30, 2026. Primary source for the 367-person study, 48-week weight-loss and A1C results, adverse-event discontinuation ranges and planned Phase 3 co-formulation with an optimized escalation schedule.
- ClinicalTrials.gov: NCT06603571 — Primary federal registry record for the Phase 2b eloralintide and tirzepatide study design and registered body-weight endpoint.
- CNBC: Eli Lilly combination obesity trial — Published September 30, 2026 at 10:15 a.m. ET. CNBC supplied the captured assignment signal and reported the issuer's efficacy and tolerability figures with company attribution.
- Photo: Eli Lilly Corporate Center, Indianapolis, Indiana, USA — File photograph by Momoneymoproblemz, taken August 1, 2019. Original pixels retained without generative alteration or upscaling; responsive article display may crop the image.
- Photo license: Creative Commons Attribution-ShareAlike 4.0 — The photograph and responsive adaptations remain under CC BY-SA 4.0. Creator credit: Momoneymoproblemz.
Read the full OptimistFi thesis on Eli Lilly and Company: https://optimistfi.com/stocks/LLY
See what would break the Eli Lilly and Company thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Eli Lilly and Company investment case, its status and the next test to watch live on the Eli Lilly and Company thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
